Advertising
Guidelines
For Aesthetic Injectors in New Zealand
Empowering safe, compliant, and ethical promotion in aesthetics
A Complete Guide for Injectors, Clinics, and Healthcare Professionals
Aesthetic Advertising Compliance in New Zealand
Why It Matters
Advertising in the aesthetic industry is not simply about promotion - it's a regulated activity that impacts client safety, your professional reputation, and public trust.
As an injector or healthcare provider in New Zealand, you are legally responsible for ensuring your advertising:
Is truthful and not misleading
Includes balanced information about risks and benefits
Promotes only on-label uses of prescription medicines
Complies with Medsafe, ASA, and the Medicines Act 1981
Non-compliance may lead to:
Formal complaints
Fines and takedowns
Professional misconduct investigations
What You Can & Can’t Do
Allowed
Promote on-label indications
Use brand names with mandatory consumer statements
Share your own, realistic before-and-afters
Say treatment "may help reduce fine lines"
Provide general educational info about treatments
Disclose paid partnerships
Not Allowed
Promote off-label uses
Use brand names without safety statements
Use stock images, celebrity photos, or pharma assets
Say it "eliminates wrinkles" or promises guaranteed results
Offer discounts, giveaways, or promotions for prescription medicines
Use testimonials or influencer reviews
On-Label vs. Off-Label Use
On-label: Medsafe-approved indications (e.g. Botox® for frown lines)
Off-label: Any other use (e.g. Botox® for lip flip)
You may perform off-label treatments with proper consent - but you cannot advertise them under NZ law.
Social Media & Digital Ad Rules
If you're promoting on platforms like Instagram, Facebook, or TikTok:
If you mention a brand name, the post must include a mandatory consumer statement.
In tight spaces (like Instagram Stories), use a short mandatory version with a visible link (e.g. to www.medsafe.govt.nz).
Mandatory statements must be:
Clear and legible
Included in the same post, not on a separate story or carousel
Applied to hashtags as well (e.g. #botoxnz still counts as a brand reference)
Mandatory Consumer Statements
When referring generic treatments or specific brand names in any form of advertising, you are legally required to include the relevant consumer statement, without any changes.
These statements are provided by the manufacturer and can also be found on Clinical Aesthetic Network New Zealand's (CANNZ) website.
If you a advertising or posting about a generic treatment (eg, no mention of a specific product) then you must also post the generic treatment consumer statement.
If you are advertising or posting about a treatment that mentions a specific product (eg, before and after Xeomin® treatment) then you must also post the brand specific consumer statement.
Find the Mandatory Consumer Statements below - copy and paste them exactly as they appear.
Short Consumer Mandatory Statement
Botulinum toxin injections are prescription medicines for the treatment of frown lines, horizontal forehead lines and crow's feet around the eyes. Botulinum toxin injections have risks and benefits. Ask your doctor if botulinum toxin injections are right for you. For further information ask your doctor or go to www.medsafe.govt.nz.
Long Consumer Mandatory Statement
Botulinum toxin injections are prescription medicine for the treatment of frown lines, horizontal forehead lines and crow's feet around the eyes. Botulinum toxin injections have risks and benefits. Ask your doctor if botulinum toxin injections are right for you. If you have side effects, see your doctor. You will need to pay for your botulinum toxin injection and clinic fees will apply. For details on precautions & side effects consult your doctor or go to www.medsafe.govt.nz. Botulinum toxin injections last about 4 months and further courses of treatment may be necessary. Should only be administered by trained medical professionals.
Short Consumer Mandatory Statement
Dermal filler injections are Medical devices for the treatment of loss of volume in the skin. Dermal fillers have risks and benefits. Ask your doctor if dermal filler injections are is right for you. For further information ask your doctor or go to www.medsafe.govt.nz
Short Consumer Mandatory Statement
PDO threads are made from polydioxanone (PDO), a biocompatible polymer which undergoes complete hydrolytic degradation. The barbs, molded along the thread, anchor into the superficial dynamic fat pads under the skin, to reposition tissue for a non-surgical lift. This can aid in reducing the signs of ageing.
Short Consumer Mandatory Statement
Belkyra® Prescription Medicine BELKYRA® injection non-surgically reduces fat under the chin, resulting in a more contoured neck profile and jawline. Belkyra® has risks and benefits. Ask your doctor if Belkyra® is right for you. Deoxycholic acid 10mg/ml. For product information check with your doctor or the Consumer Medicine Information on www.medsafe.govt.nz. Allergan (NZ) Limited, Auckland.
Long Consumer Mandatory Statement
BELKYRA® injection is a prescription medicine containing 10mg/mL deoxycholic acid. It is used for the improvement in the appearance of moderate to severe convexity or fullness associated with fat below the jaws in adults. Do not use in people allergic to this medicine, with infection at site of injection, pregnancy, and lactation. Possible side effects include headaches, difficulty swallowing, nausea, skin tightness, hypertension, injection site bruising/pain/swelling/numbness/redness/tingling/hardness/itching/discolouration/formation of small areas of hardness/warmth and injection site nerve injury. BELKYRA® treatment is not funded on the New Zealand Pharmaceutical Schedule. You will need to pay for this medicine. Normal Doctors visit fees apply. BELKYRA® treatment should be administered only by trained medical professionals. Speak to your specialist about your own situation and about the benefits/risks of this procedure in appearance medicine. For further information, the Data Sheet and Consumer Medicines Information can be accessed at www.medsafe.govt.nz or ask your doctor. If you have any side effects or concerns speak to your doctor. Note: Results from BELKYRA® treatment usually last up to 4 years. Allergan New Zealand Limited, Auckland.
Short Consumer Mandatory Statement
Belotero® Medical Device Class III to smooth facial wrinkles and folds, correct facial atrophic scars, restore or enhance the lips or restore facial volume Belotero® has risk and benefits. Ask your doctor if Belotero is right for you. For product information check with your doctor or from product details with the supplier. Contains Sodium Hyaluronate Gel. Merz, Sydney. Distributed by Healthcare Logistics, Auckland.
Long Consumer Mandatory Statement
Belotero® is a Class III medical device to smooth facial wrinkles and folds, correct facial atrophic scars, restore of enhance the lips or restore facial volume. Belotero has risk and benefits. Ask your specialist if Belotero® is right for you. Contains transparent cross-linked sodium hyaluronate gel of nonanimal origin with lidocaine 0.3% to reduce local pain. Do not use if you have a skin inflammation or a skin infection or until the infection is healed. Precautions. There is a risk of infection. Tell your doctor if you are on blood-clotting medicines as there could be an increased risk of bruising or bleeding at the injection site. Possible side effects: swelling, bruising, redness hardening of the skin, pain, altered colour or itching. Lasts 6-12 months. You will need to pay for this product and doctor's fees apply. Merz, Sydney. Distributed by Healthcare Logistics, Auckland.
BELOTERO® Revive is an injectable resorbable implant intended to revitalize facial skin through rehydration of dry and very dry skin, improvement of elasticity and firmness, and smoothening of superficial fine lines by reducing skin roughness. Belotero® Revive is indicated for revitalization of early-onset photodamaged facial skin, as characterized by dehydration, loss of elasticity and firmness, and presence of superficial fine lines. You should tell your practitioner and avoid treatment with BELOTERO® Revive if you: have had an allergic reaction to any of the ingredients; if you tend to develop keloids or heavy scars; have any bleeding disorders, poor wound healing, inflamed or infected skin, active auto-immune disease or general infection; are under the age of 18; are pregnant or breastfeeding. Please inform your practitioner of any diseases you have or have had. These include in particular cardiovascular diseases, autoimmune diseases, diabetes, epilepsy, liver or kidney problems, skin infections or severe allergies. If you take medication or vitamins, have had previous cosmetic procedures, or have been treated with other implants, please inform your practitioner. Always read the label and consult your Healthcare Professional for more information. This medical device must be administered by a Healthcare Professional. Copyright © 2023. Pharmacy Retailing NZ Limited t/a Health Care Logistics (HCL) 58 Richard Pearse Drive, Mangere, Auckland 2022. All rights reserved. Belotero® and Merz Aesthetics are registered trademarks of Merz Pharma GMbH & Co. KGaA.
Short Consumer Mandatory Statement
Botox®, Prescription Medicine for the treatment of frown lines and crow's feet around the eyes. Botox® has risks and benefits. Ask your doctor if Botox® is right for you. Botulinum toxin type A 50, 100, 200 Units. For product information check with your doctor or Consumer Medicine Information on www.medsafe.govt.nz. Allergan, Auckland.
Long Consumer Mandatory Statement
Botox® is a prescription medicine containing 100 units of Clostridium Botulinum Type A toxin complex for injection. It is used for the treatment of severe frown lines and associated "crow's feet" around the eyes. It should be administered only by trained medical professionals. Talk to your specialists about the benefits/risks of this procedure in appearance medicine. Cautions: people with neuro-muscular transmission disorders, presence of infection at site of injection, pregnancy and lactation. Possible side effects include headaches, pain, burning sensation or redness at injection site, temporary local muscle weakness including eyelid droop, decreased sensation and nausea. If you have side effects or concerns, talk to your doctor. A charge applies. Allergan Pharmaceutical, Auckland.
Short Consumer Mandatory Statement
Dysport®, Prescription Medicine for the treatment of frown lines and crow's feet around the eyes. Dysport® has risks and benefits. Ask your doctor if Dysport® is right for you. Botulinum toxin type A 300 or 500 Ipsen Units. For product information check with your doctor or Consumer Medicine Information on www.medsafe.govt.nz. Click for further details Galderma, Auckland.
Long Consumer Mandatory Statement
Dysport® is a prescription medicine for the treatment of frown lines, horizontal forehead lines and crow's feet around the eyes. Dysport® has risks and benefits. Ask your doctor if Dysport is right for you. If you have side effects see your doctor. You will need to pay for Dysport, and clinic fees will apply. For details on precautions & side effects consult your healthcare professional or the Consumer Medicine Information (CMI) at www.medsafe.govt.nz. Dysport lasts about 4-6 months and further courses of treatment may be necessary. Should only be administered by trained medical professionals. Contains 500 units of clostridium botulinum Type A toxin. Galderma (NZ) Limited, Auckland.
e.p.t.q. Lidocaine is a sterile, non-pyrogenic, viscoelastic, colourless, transparent gel composed of cross-linked sodium hyaluronate gel of non-animal origin with 0.3% lidocaine hydrochloride in a physiologic phosphate buffer. e.p.t.q. Lidocaine is an injectable gel (also called a dermal filler) used for the correction of nasolabial folds. e.p.t.q. Lidocaine is produced with hyaluronic acid (HA), the HA of the gel is made from a non-animal source. e.p.t.q. Lidocaine should not be used on patients: with known hypersensitivity to any of its components; presenting with a general infection, inflammatory or infectious cutaneous problems; with history of severe multiple allergies or anaphylactic shock; prone to hypertrophic scars/keloids or streptococcal diseases; in patients presenting with porphyria; under 18 years of age; in pregnancy or lactation; others. See full Instructions for Use before prescribing for full safety information, available from www.xytide.co.nz. Copyright© 2024. Xytide Biotech Pty Ltd. Always read the label and follow the instructions. This medical device must be administered by a Healthcare Professional. New Zealand Sponsor Xytide Biotech NZ Pty Ltd (NZBN 9429049668612) C/O Alliott Ltd, Level 2, 142 Broadway, Newmarket, Auckland 1023 NZ. For more information please phone +61 1800 570 036
Short Consumer Mandatory Statement
JALUPRO® Superhydro is a sterile resorbable injectable solution which acts as a deep biorevitalization treatment of Amino Acids Replacement Therapy, combined with biopeptides and a high concentration of high and low molecular weight hyaluronic acid. JALUPRO® Superhydro aims at supporting deep connective tissue, facial retaining ligaments and retinacular cutis, supporting the restoration of physiological condition. Distributed by EnVogue Skin NZ Pty Ltd. EnVogue Skin Pty Ltd. ABN 98 620 276 762. All brands and product names mentioned are trademarks of their respective holders. Copyright © 2024. All rights reserved.
Long Consumer Mandatory Statement
Jalupro Super Hydro: IMPORTANT INFORMATION: JALUPRO® Superhydro is a sterile resorbable injectable solution which acts as a deep biorevitalization treatment of Amino Acids Replacement Therapy, combined with biopeptides and a high concentration of high and low molecular weight hyaluronic acid. JALUPRO® Superhydro aims at supporting deep connective tissue, facial retaining ligaments and retinacular cutis, supporting the restoration of physiological condition, minimising the signs of aging, correcting the imperfections and defect of skin tissue. JALUPRO is composed of a pre filled syringe containing Amino Acids (Glycine, L-Proline, L-Leucine, L-Lysine), biopeptides and 32mg/ml hyaluronic acid. You should not receive treatment with any JALUPRO® SuperHydro product if you are below 18 years of age, if you are pregnant or breastfeeding, hypersensitivity to ingredients including hyaluronic acid, lidocaine or amide-type local anaesthetics, any areas of cutaneous inflammation and/or infections. Avoid makeup for 12 hours after injection and prolonged exposure to sunlight/UV light/extreme temperatures for 2 weeks. Distributed by EnVogue Skin NZ Pty Ltd. EnVogue Skin Pty Ltd. ABN 98 620 276 762. All brands and product names mentioned are trademarks of their respective holders. Copyright © 2024. All rights reserved.
Short Consumer Mandatory Statement
Juvederm Ultra™ & Ultra Plus™, Medical Device Class III. For the filling of medium size and deep facial wrinkles by injection into the skin. Juvederm™ has risks and benefits. Ask your doctor if Juvederm™ is right for you. Volume (mL) 0.8mL Volume (mL) 1.0m hyaluronic acid + lidocaine. For product information check with your doctor or from product details with the supplier. Allergan, Auckland.
Long Consumer Mandatory Statement
Juvederm Ultra™ & Juvederm Ultra Plus™ are medical devices Class III for the filling of medium size and deep facial wrinkles by injection into the skin and for creating definition and volume in the lips. Contains 24mg/mL cross-linked hyaluronic acid. Juvederm has risks and benefits. Cautions: Use in an area that has been treated with another dermal filler, people with autoimmune disease, or who are pregnant, breastfeeding, under 18 years of age or have an increased susceptibility to keloid formation and hypertrophic scarring. People on blood thinning medicines. Possible side effects: injection site inflammatory reactions (redness/swelling, itching/pain on pressure) induration or nodules; discolouration; weak filling effect. If you have side effects or concerns speak to your doctor. Product and treatment costs will apply. Note: Juvederm treatment lasts about 12-24 months. For product information check with your doctor or product information at Allergan (NZ) Limited, Auckland.
MINT™ stands for "Minimally Invasive Non-surgical Thread". The threads are made from polydioxanone (PDO), a biocompatible polymer which undergoes complete hydrolytic degradation. The barbs, molded along the thread, anchor into the superficial dynamic fat pads under the skin, to reposition tissue for a non-surgical lift. This can aid in reducing the signs of ageing. Distributed by Mondeal Pty Ltd.
Short Consumer Mandatory Statement
Profhilo® Medical Device Class III. For the redefinition and laxity remodelling where skin laxity is a problem. Profhilo has risks and benefits. Contains low & high molecular weight hyaluronic acid (64mg/2ml). Ask your doctor if Profhilo is right for you. For product information check with your doctor or from product details with the Distributor Healthcare Logistics, Auckland.
Long Consumer Mandatory Statement
Profhilo®, containing low & high molecular weight hyaluronic acid, is a Class III medical device for the treatment of the face and body for contours redefinition and laxity remodelling where skin laxity is a problem. Profhilo® has risks and benefits. Do not use with treatments such a laser resurfacing or medium deep skin-peeling. Caution in people on blood thinning medicines. Do not inject into inflamed areas or intravenously or intramuscularly. Possible side effects: pain and swelling at injection site. Please refer to instructions for use, local distributor. Healthcare Logistics, Auckland.
Radiesse® injectable implant is intended for plastic and reconstructive surgery, including deep dermal and sub-dermal soft tissue augmentation of the facial area and dorsum of the hands. Radiesse® injectable implant is indicated for: the treatment of nasolabial folds, marionette lines or jawline; the augmentation of cheeks; the hand augmentation to correct volume loss in the dorsum of the hands; and the restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus. Radiesse® (+) Lidocaine injectable implant is intended for plastic and reconstructive surgery, including deep dermal and sub-dermal soft tissue augmentation of the facial area and dorsum of the hands in adults. Radiesse® (+) Lidocaine injectable implant is indicated for: the treatment of nasolabial folds, marionette lines and jawline; the augmentation of cheeks; hand augmentation to correct volume loss in the dorsum of the hands; the restoration and/or correction of the signs of fat or volume loss (lipoatrophy) in the facial area and for rejuvenation of the hands fat loss (lipoatrophy) in people with human immunodeficiency virus. You should tell your practitioner and avoid treatment with Radiesse®/Radiesse® (+) Lidocaine if you: have had an allergic reaction to any of the ingredients or have severe allergies including anaphylaxis; if you tend to develop keloids or heavy scars; have any bleeding disorders, poor wound healing; inflamed or infected skin; are under the age of 18; are pregnant or breastfeeding. Please inform your practitioner of any diseases you have or have had. These include in particular cardiovascular diseases, autoimmune diseases, diabetes, tumors, skin infections or severe allergies. If you take medication or vitamins, have had previous cosmetic procedures, or have been treated with other implants, please inform your practitioner. Always read the label and consult your Healthcare Professional for more information. This medical device must be administered by a Healthcare Professional. Merz Australia Pty Ltd (ACN: 151 073 559) Sydney, Australia. NZ Distribution: Pharmacy Retailing NZ Limited t/a Health Care Logistics (HCL). 58 Richard Pearse Drive, Mangere, Auckland 2022. For more information please phone 0800 822 310.
Short Consumer Mandatory Statement
Restylane®, Medical Device Class III to smooth facial wrinkles and enhance lips by restoring volume and fullness. Restylane® has risk and benefits. Ask your doctor if Restylane® is right for you. For product information check with your doctor or from product details with the supplier. Stabilised Hyaluronic Acid 20mg/ml. Galderma, Australia, Sydney or distributor Healthcare Logistics, Auckland.
Long Consumer Mandatory Statement
Restylane® is a gel containing hyaluronic acid and lidocaine that is injected by a healthcare professional into or below the skin to smooth facial wrinkles and enhance lips by restoring volume and fullness. Restylane is a Class III medical device and has risks and benefits. Restylane® treatment may result in some redness, swelling, pain or tenderness, itching and/or bruising which may last a few days. Inflammatory reactions can begin up to two to four weeks after treatment in rare cases. See your healthcare professional if any side effects concern you. Exposure to excessive sunlight or extreme cold should be avoided until redness or swelling has resolved. Restylane® should not be used in an area where there is a nonresorbable implant or in irritated or infected skin, Restylane® should not be used in people taking blood thinning medicines or who have an allergy to hyaluronic acid, lidocaine or other local anaesthetics. Caution if you take medicines that prolong bleeding time. Treatment lasts 12-24 months. Restylane has not been tested in pregnant or breast-feeding women. ALWAYS FOLLOW THE INSTRUCTIONS YOU ARE GIVEN. Galderma, Auckland. Distributed by Healthcare Logistics, Auckland.
Short Consumer Mandatory Statement
Restylane® Skinboosters Medical Device Class III. For the treatment of skin structure, hydration and elasticity. Restylane Skinboosters has risks and benefits. Ask your doctor if Restylane Skinboosters is right for you. 20mg/ml stabilised hyaluronic acid. For product information check with your doctor or from product details with the supplier. Galderma Australia Sydney or distributor Healthcare Logistics, Auckland.
Long Consumer Mandatory Statement
Restylane® Skinboosters is a gel containing hyaluronic acid that is injected into or below the skin to improve skin structure, hydration and elasticity. Restylane® Skinboosters is a medical device class III that has risks and benefits. Do not use in patients with bleeding disorders, or in patients taking blood thinning medicines. Do not inject intravascularly, where there is active disease, inflammation, infection, or tumours near the intended treatment site. Possible side effects are injection site effects like swelling, bruising, and tenderness and inflammation. Treatment usually lasts 6-12 months. Product and treatment costs will apply. Consult your cosmetic practitioner for further information. Further product details can also be found in the full product information. Galderma, Auckland.
Short Consumer Mandatory Statement
Sculptra® Medical Device Class III to increase volume of depressed areas, particularly to correct skin depressions. Sculptra has risks and benefits. Contains Poly-L-Lactic acid implant suspension. Ask your doctor if Sculptra® is right for you. For product information check with your doctor or from product details with the supplier. Galderma Australia Sydney. Distributed by Healthcare Logistics, Auckland.
Long Consumer Mandatory Statement
Sculptra® is a poly-L-lactic acid implant liquid that is injected by a healthcare professional into or below the skin to increase volume of depressed areas, particularly to correct skin depressions. Class III Medical Device. Sculptra® may also be used for large volume restoration and/or correction of the signs of facial fat loss. Sculptra® has risks and benefits. Sculptra® treatment may result in injection site reactions and pain. Ask your healthcare professional to explain the range of possible side effects and tell them if any side effects concern you. Sculptra® should not be injected into skin that is inflamed or infected. Exposure to excessive sunlight or UV lamp exposure should be avoided until redness or swelling has resolved. Sculptra® is not recommended for people taking blood thinning medicines and has not been tested in pregnant or breast-feeding women or those aged under 18 years. Lasts for 12-25 months. ALWAYS FOLLOW THE INSTRUCTIONS YOU ARE GIVEN. Galderma Australia, Sydney. Distributed by Healthcare Logistics Auckland.
STYLAGE® S Lidocaine (16mg/mL), STYLAGE® M Lidocaine™ (20mg/mL), STYLAGE® L Lidocaine™(24mg/mL), STYLAGE® XL Lidocaine™(26mg/mL), STYLAGE® XXL™(21mg/mL), and STYLAGE® Lips Plus are hyaluronic acid injectable gel classified as medical devices Class III for the filling of medium size and deep facial wrinkles by injection into the skin and for redefining lip and/or augmenting lip volume. Contains transparent cross-linked sodium hyaluronate gel of non-animal origin with lidocaine 0.3% to reduce the pain associated with the injection. Cautions: people with autoimmune disease, or who are pregnant, breastfeeding, under 18 years of age or have an increased susceptibility to keloid formation and hypertrophic scarring. People on blood thinning medicines. Possible side effects: injection site inflammatory reactions (redness/swelling, itching/pain on pressure) induration or nodules; discolouration. You will need to pay for this product and doctor’s fees apply. If you have side effects or concerns speak to your practitioner. Distributed by EnVogue Skin NZ Pty Ltd. EnVogue Skin Pty Ltd. ABN 98 620 276 762. All brands and product names mentioned are trademarks of their respective holders. Copyright © 2023. All rights reserved.
STYLAGE® Lips Plus (20mg/mL) IPN-Like Cross-linked Hyaluronic acid gel of non-animal origin with Mannitol and 0.3% Lidocaine is classified as medical devices Class III specially indicated for redefining lip and/or augmenting lip volume. Only to be administered by appropriately trained healthcare professionals who are qualified or accredited in accordance with national law. Always read and follow the instructions. If you have side effects or concerns speak to your practitioner. Distributed by EnVogue Skin NZ Pty Ltd. EnVogue Skin Pty Ltd. ABN 98 620 276 762. All brands and product names mentioned are trademarks of their respective holders. Copyright © 2023. All rights reserved.
Sunekos containing hyaluronic acid and amino acids is a class III medical device that modifies the structure of mature skin, restoring volume, filling wrinkles and folds in the skin and in scar sites. Sunekos has risks and benefits. Sunekos should not be used on patients: with known hypersensitivity to any of its components; presenting with a general infection, inflammation or irritation in the area to be treated; or in patients predisposed to coagulation disorders. A local reaction may rarely occur, caused by hypersensitisation phenomena, with symptoms that include oedema and sensation of burning and/or itching. These reactions normally resolve within two days. Consult your healthcare professional to see if Sunekos is right for you. For more information refer to the instructions for use. New Zealand Sponsor: AA-Med Pty Ltd. Distributed by: Xytide Biotech NZ Pty LTD.
Sunekos 1200 is an implantable medical device that modifies the structure of mature skin, restoring volume, filling wrinkles and folds in the skin and in scar sites. It is suitable for creating a temporary increase in the volume of skin tissue. Sunekos 1200 is a medical device that is sterile, injectable, non-pyrogenic, biocompatible, re-absorbable, made with hyaluronic acid and amino acids. Sunekos Performa is a medical device recommended for the treatment of blemishes and depressions in the skin caused by wrinkles and scars. Sunekos Performa is a sterile resorbable injectable solution which acts as a filler, supporting the restoration of physiological elasticity and temporarily replacing volume by expanding the soft tissues. Sunekos should not be used on patients: with known hypersensitivity to any of its components; presenting with a general infection, inflammatory or infectious cutaneous problems; with history of severe multiple allergies or anaphylactic shock; prone to hypertrophic scars/keloids or streptococcal diseases; in patients presenting with porphyria; under 18 years of age; in pregnancy or lactation; others. See full Instructions for use before prescribing for full safety information, available from www.xytide.co.nz New Zealand Sponsor: AA-Med Pty Ltd Distributed by: Xytide Biotech NZ Pty Ltd (NZBN 9429049668612) C/O Alliott Ltd, Level 2, 142 Broadway, Newmarket, Auckland 1023 NZ. For more information please phone +61 1800 570 036.
Short Consumer Mandatory Statement
Teosyal® from Teoxane® Medical Device Class III is a space-occupying supplement to correct skin contour deformities (e.g. wrinkles, folds, scars especially around the eyes). Teosyal® has risks and benefits. Contains Hyaluronic Acid in various volumes with lidocaine 0.3% by mass. Ask your doctor if Teosyal® is right for you. For product information check with your doctor or from the supplier. Distributed by Healthcare Logistics Auckland.
Long Consumer Mandatory Statement
TEOSYAL RHA® 1, TEOSYAL RHA® 2, TEOSYAL RHA® 3, TEOSYAL RHA® 4, TEOSYAL® PURESENSE REDENSITY 1, TEOSYAL® PURESENSE REDENSITY 2, TEOSYAL PURESENSE KISS®, TEOSYAL® PURESENSE GLOBAL ACTION, TEOSYAL® PURESENSE DEEP LINES, TEOSYAL® PURESENSE ULTIMATE and TEOSYAL® PURESENSE ULTRA DEEP TEOSYAL KISS®, RHA KISS®, TEOSYAL® MESO, TEOSYAL® GLOBAL ACTION, TEOSYAL® DEEP LINES, TEOSYAL® ULTIMATE and TEOSYAL® ULTRA DEEP are trademarks of the firm TEOXANE SA. These products are gel that contains hyaluronic acid, and 0.3% by weight of lidocaine hydrochloride. They are class III medical devices. Caution for people on blood thinning medicines. Local side effects: inflammatory reactions (redness, oedema, pain at the point of injection), haematomas, itching, temporary loss of sensitivity around the injected area, disorders of pigmentation in skin and hair, abscesses, indurations, nodules (possibly granulomas). General manifestations: immediate hypersensitivity up to anaphylactic shock, migration of the implant. Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment or blindness, skin necrosis and stroke. Lasts 9-12 months. Please consult your doctor pharmacist for more information. Please refer to instructions for use, local distributor. Healthcare Logistics, Auckland.
Short Consumer Mandatory Statement
Xeomin® (incobotulinum toxin) Prescription Medicine for the treatment of upper facial lines: glabellar frown lines, crow's feet round the eyes, horizontal forehead lines. Xeomin® has risks and benefits. Ask your doctor if Xeomin® is right for you (incobotulinum toxin A, purified Botulinum toxin type A 50 Units and 100 Units). For product information check with your doctor or Consumer Medicine Information on www.medsafe.govt.nz. Merz, Sydney. Distributed by Healthcare Logistics, Auckland.
Long Consumer Mandatory Statement
Xeomin® is a Prescription Medicine containing 50, 100 units of incobotulinum Type A, purified Botulinum toxin type A complex for injection. It is used for the treatment of frown lines on the forehead, lateral periorbital lines and horizontal forehead lines in adults. It should be administered only by trained medical professionals. Talk to your specialist about the benefits/risks of this procedure in appearance medicine. Xeomin® treatment lasts about four months and further courses of treatment may be necessary. Cautions: people receiving blood thinning medicines, care at the proposed injection sites, pregnancy and lactation. Possible side effects: headache, pain, swelling or infection at injection site, local muscle weakness including drooping eye lids, lack of feeling & nausea. Treatment last for up to 4 months. You will need to pay for this medicine. Discuss with your specialist if Xeomin® is right for you. For more information or for a copy of CMI please contact the NZ distributor: Merz, Sydney. Distributed by Healthcare Logistics, Auckland.
Disclaimer:The information provided on this page is intended as general guidance for aesthetic practitioners in New Zealand. While MObyJC strives to ensure the accuracy and currency of the content, we do not accept responsibility for any errors, omissions, or outcomes resulting from its use. Practitioners are advised to consult the official Medsafe guidelines and seek independent legal advice to ensure compliance with all advertising requirements. MObyJC is not liable for any non-compliance arising from reliance on the information provided herein.
Ready to supercharge your clinic?
Get In Touch
Connect with us today to explore how MO by JC can support you in building a safe, reputable, and thriving practice. Together, let’s make your journey as an aesthetic injector secure, empowering, and rewarding.
